Shen, Lianjun

Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells

Zhou, Z., He, H., Wang, K., Shi, X., Wang, Y., Su, Y., Wang, Y., Li, D., Liu, W., Zhang, Y., et al. (2020) · Science

Inflammasome and immune disordersCell death mechanisms and regulation

Cited by 1,317

Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM).

Du, J., Fu, W.-J., Jiang, H., Dong, B., Gao, L., Liu, L., Ge, J., He, A., Li, L., Lu, J., et al. (2023) · Journal of Clinical Oncology

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 35

Updated Results of a Phase I Open-Label Single-Arm Study of Dual Targeting BCMA and CD19 Fastcar-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma

Du, J., Qiang, W., Lu, J., Jia, Y., He, H., Liu, J., Guo, P., Yang, Y., Feng, Z., Jin, L., et al. (2023) · Blood

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 21

A feasibility and safety study of a new CD19-directed fast CAR-T therapy for refractory and relapsed B cell acute lymphoblastic leukemia

Yang, J., He, J., Zhang, X., Wang, Z., Zhang, Y., Cai, S., Sun, Z., Ye, X., He, Y., Shen, L., et al. (2019) · Blood

CAR-T cell therapy researchAcute Lymphoblastic Leukemia research

Cited by 20

CD19-directed fast CART therapy for relapsed/refractory acute lymphoblastic leukemia: from bench to bedside

Zhang, C., He, J., Liu, L., Wang, J., Wang, S., Liu, L., Gao, L., Gao, L., Liu, Y., Kong, P., et al. (2019) · Blood

CAR-T cell therapy researchAcute Lymphoblastic Leukemia research

Cited by 17